chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia, Vomiting
Clinical narrative: Headache; fever ranging from 99 - 101; Shortness of breath; Fatigue; Body ache; Nausea; Vomiting; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200), via an unspecified route of administration in the left arm on 04Mar2021 at 15:15 (at the age of 65-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure (HBP), obesity, type 2 diabetes, asthma and COVID-19 in Mar2020 and Apr2020. It was reported that the patient was on unspecified concomitant medications. The patient had no known allergies. The patient did not receive any other vaccines within four weeks, prior to the COVID-19 vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  On 05Mar2021 at 02:30, the patient experienced, headache, fever ranging from 99 - 101, shortness of breath, fatigue, body aches, nausea, vomiting, and diarrhea. The symptoms lasted for about forty hours after they began. The events resulted in doctor or other healthcare professional office or clinic visit. Therapeutic measures taken included tylenol (MANUFACTURER UNKNOWN) for fever and ondansetron (MANUFACTURER UNKNOWN) for nausea. The clinical outcome of the events headache, fever, shortness of breath, fatigue, body ache, nausea, vomiting and diarrhea were resolved on 07Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Injection site pain, Nausea
Clinical narrative: Nausea; headache; tiredness; very strong muscle pain at injection site; This is a spontaneous report received from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8734) via an unspecified route of administration in the right arm on 30Mar2021 at 12:30 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included autonomic seizures, hypothyroidism and migraines. Concomitant medications included levetiracetam (KEPPRA), lamotrigine(LAMICTAL ER), rizatriptan benzoate (MAXALT), levothyroxine(MANUFACTURER UNKNOWN) and paracetamol(TYLENOL), all from unknown dates and for unknown indications. The patient had allergies to tramadol, naproxen, ibuprofen and prozac. The patient did not receive any other vaccine in four weeks prior to COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 30Mar2021 at 13:00, the patient experienced nausea, very strong muscle pain at injection site, headache and tiredness. The patient did not receive any treatments for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events nausea, very strong muscle pain at injection site, headache and tiredness was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Feeling abnormal, Headache
Clinical narrative: Intense skin sensitivity; intense headache; chills; body aches; could not lift left arm; nausea; vomiting; Dizziness; Bit fuzzy; Tired; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the arm left on 29Mar2021 at 10:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies, herpes or fever blisters (fever blisters) and anxiety. Concomitant medications included cetirizine hydrochloride (ZYRTEC), triamcinolone acetonide (NASACORT), sertraline hydrochloride (ZOLOFT), aciclovir sodium (ACYCLOVIR), and spironolactone (ALDACTONE) all taken from unspecified dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the arm left on 08Mar2021 at 10:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 29Mar2021, the patient experienced dizziness immediately after vaccine administration of second dose, fuzzy and tired afterwards. On 29Mar2021 at 15:00, the patient experienced chills, intense headache, body aches, and pain in arm (not able to lift left arm), overnight chills increased, and experienced nausea and vomiting. On 30Mar2021, the patient was too nauseous, and had intense skin sensitivity. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events dizziness, bit fuzzy, tired, chills, intense headache, body aches, could not lift left arm, nausea, vomiting, and intense skin sensitivity were resolved on unspecified dates in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pain in extremity, Sensitive skin, Vomiting
Clinical narrative: Intense skin sensitivity; intense headache; chills; body aches; could not lift left arm; nausea; vomiting; Dizziness; Bit fuzzy; Tired; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the arm left on 29Mar2021 at 10:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies, herpes or fever blisters (fever blisters) and anxiety. Concomitant medications included cetirizine hydrochloride (ZYRTEC), triamcinolone acetonide (NASACORT), sertraline hydrochloride (ZOLOFT), aciclovir sodium (ACYCLOVIR), and spironolactone (ALDACTONE) all taken from unspecified dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the arm left on 08Mar2021 at 10:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 29Mar2021, the patient experienced dizziness immediately after vaccine administration of second dose, fuzzy and tired afterwards. On 29Mar2021 at 15:00, the patient experienced chills, intense headache, body aches, and pain in arm (not able to lift left arm), overnight chills increased, and experienced nausea and vomiting. On 30Mar2021, the patient was too nauseous, and had intense skin sensitivity. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events dizziness, bit fuzzy, tired, chills, intense headache, body aches, could not lift left arm, nausea, vomiting, and intense skin sensitivity were resolved on unspecified dates in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Vertigo
Clinical narrative: Extreme vertigo; dizziness; fatigue; This is a spontaneous report from a contactable health care professional, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20Mar2021 at 14:30 (at the age of 32-yeasr-old) as a single dose for COVID-19 immunisation. Medical history included migraine. Concomitant medications included eletriptan hydrobromide (RELPAX), vitamin d nos (VITAMIN D), ascorbic acid (VITAMIN C), ibuprofen (ADVIL), prenatal vitamin (MANUFACTURER UNKNOWN) on unknown date for unspecified indication received within 2 weeks of vaccination. The patient previously received ciprofloxacin (MANUFACTURER UNKNOWN), COMPAZINE and lactose (MANUFACTURER UNKNOWN) and had drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination.  Prior to the vaccination, whether the patient was diagnosed with COVID-19, was unknown. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021 at 12:00, the patient experienced extreme vertigo, dizziness and fatigue. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown if treatment was received for the reported events. The clinical outcome of the events extreme vertigo, dizziness and fatigue was not recovered at the time of this report.   No follow attempts are needed; Information about lot number cannot be obtained.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pruritus
Clinical narrative: Sore arm; Itchy feets; Itchy hands; This is a spontaneous report from a non-contactable consumer, the patient. A 51-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the arm left on 24Mar2021 at 09:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation.  Medical history was not reported. The patient had no known allergy. Concomitant medications included ibuprofen sodium (MANUFACTURER UNKNOWN) started on an unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 at 10:30 the patient experienced sore arm, for 36 hours after vaccine, itchy hands and feet 1 hour after vaccine that lasted 1 hour and the same irritation occurred the second morning after the vaccine for about 2 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event sore arm resolved on 26Mar2021 at 22:30 and that of events itchy feet and itchy hands was resolved with sequelae on 24Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pyrexia, Vomiting
Clinical narrative: Had a fever; Chills; Headache; Had major vomiting 8 times; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6207), via an unspecified route of administration in the left arm on 29Mar2021 at 11:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. Medical history included ulcerative colitis, arthritis, shellfish allergy and allergy to bee stings. Concomitant medications included prednisone (MANUFACTURER UNKNOWN), hydrochlorothiazide (HCTZ), calcium (MANUFACTURER UNKNOWN) and ergocalciferol (VITAMIN D); all for unknown indications from unknown date. The patient previously took erythromycin (MANUFACTURER UNKNOWN) for an unspecified indication and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: En6203), via an unspecified route of administration in the left arm on 08Mar2021 at 11:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks of vaccination. On 29Mar2021 at 23:00, 12 hours post vaccination, the patient experienced fever, chills, headache, and major vomiting 8 times within short period of time. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fever, chills, headache and vomiting was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Dyspnoea, Vertigo
Clinical narrative: I usually walk 2 miles and go up a hill,a couple of days felt short breath.; I started to feel dizzy.; Vertigo; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 16Mar2021 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. The medical history was reported as none. The concomitant medications of the patient included vitamin b complex (MANUFACTURER UNKNOWN), vitamin c (MANUFACTURER UNKNOWN), vitamin d (MANUFACTURER UNKNOWN), and biotin (MANUFACTURER UNKNOWN). The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021, the patient experienced the events dizziness, vertigo.The patient used to walk 2 miles and go up a hill and on 22Mar2021, she felt shortness of breath for a couple of days. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events dizziness, vertigo and shortness of breath was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure abnormal, Blood pressure measurement, Fatigue, Headache, Palpitations
Clinical narrative: Heart racing within minutes of the shot; Sporadic strong headaches; Sporadic fatigue; Blood pressure (BP); This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: PFER8727) via an unspecified route of administration in the left arm on 20Mar2021 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high (HBP), cardiovascular disease and gout. The patient had a history of allergy to sulpha based medications, penicillin and statins. Concomitant medications included aspirin (MANUFACTURER UNKNOWN), blood pressure (unspecified medication) and blood thinners (unspecified medication); all for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021, the patient had heart racing within minutes of the shot; she also experienced sporadic strong headaches, which lasted for about 60 seconds for 24-48 hours and had sporadic fatigue. On an unknown date in Mar2021, the patient had blood pressure (BP). The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measure was taken as a result of blood pressure (BP) and included treatment with clonidine, the patient took extra clonidine 0.05 mg to lower BP. The clinical outcomes of the events heart racing, headache and fatigue were resolved on an unknown date in Mar2021 while that of blood pressure abnormal was unknown at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Heart rate increased, Vision blurred
Clinical narrative: Rapid heartbeat; Spotty vision; Shortness of breath; This is a spontaneous report from a contactable consumer, the patient. A 27-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 31Mar2021 at 13:15 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included heart palpitations. The patient was allergic to past drugs acetaminophen (MANUFACTURER UNKNOWN) and montelukast sodium (SINGULAIR). Concomitant medications included propranolol (80mg) (MANUFACTURER UNKNOWN) and lisdexamfetamine mesilate (VYVANSE) (50mg) and an unspecified birth control medication (MANUFACTURER UNKNOWN), all from unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 31Mar2021 at 14:30, the patient experienced rapid heartbeat, spotty vision, and shortness of breath. It was reported that all symptoms were mild. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcomes of rapid heartbeat, spotty vision and shortness of breath was unknown.  No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Lethargy, Pyrexia
Clinical narrative: Very lethargic; Severe chills; fever up to 101; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 29Mar2021 at 13:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient was allergic to sulpha drugs. The patient previously also received BACTRIUM and experienced drug allergy.   Concomitant medications included olmesartan 20 mg (MEDOXOMIL), naproxen (MANUFACTURER UNKNOWN) and Fexofenadine hydrochloride (FEXOFENADIN) for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 30Mar2021, the patient experienced severe chills, fever up to 101 (unspecified unit) and patient was very lethargic. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events severe chills, fever up to 101 and very lethargic was resolved on an unknown date in Mar2021.    No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in the ear all the time; This is a spontaneous report from a non-contactable consumer, the patient. A 65-years old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on an unknown date in Mar2021 (at the age of 65-year-old) as a single dose for COVID-19 immunisation. The patient was allergic to sulfa. Concomitant medications included lexapro (MANUFACTURER UNKNOWN) from an unknown date and atarax (MANUFACTURER UNKNOWN) from an unknown date and for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 30Mar2021, the patient experienced ringing in the ear all the time. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event ringing in the ear all the time was not resolved.  No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Cold sweat, Headache, Pain
Clinical narrative: severe body aches; Headache; Chills; Fever of 100.3; Cold sweats; This is a spontaneous report from a non-contactable consumer, the patient. A 21-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 30Mar2021 at 11:00 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to peanuts, cashews and walnuts. Concomitant medications included hydroxyzine (MANUFACTURER UNKNOWN), sertraline (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC) and bupropion hydrochloride (WELLBUTRIN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 10Mar2021 at 14:30 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 20:15 (reported as night after booster shot), the patient experienced headache, chills, cold sweats and fever of 100.3. On 31Mar2021 (reported as day after booster), the patient experienced severe body aches, 100.3 fever, chills and headache. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events headache, chills, cold sweats, fever of 100.3 and severe body aches which included treatment with ibuprofen (MANUFACTURER UNKNOWN), acetaminophen; dextromethorphan; phenylephrine (DAYQUIL) and NYQUIL. The clinical outcomes of the events headache, chills, cold sweats, fever of 100.3 and severe body aches were resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: severe body aches; Headache; Chills; Fever of 100.3; Cold sweats; This is a spontaneous report from a non-contactable consumer, the patient. A 21-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 30Mar2021 at 11:00 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to peanuts, cashews and walnuts. Concomitant medications included hydroxyzine (MANUFACTURER UNKNOWN), sertraline (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC) and bupropion hydrochloride (WELLBUTRIN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 10Mar2021 at 14:30 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 20:15 (reported as night after booster shot), the patient experienced headache, chills, cold sweats and fever of 100.3. On 31Mar2021 (reported as day after booster), the patient experienced severe body aches, 100.3 fever, chills and headache. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events headache, chills, cold sweats, fever of 100.3 and severe body aches which included treatment with ibuprofen (MANUFACTURER UNKNOWN), acetaminophen; dextromethorphan; phenylephrine (DAYQUIL) and NYQUIL. The clinical outcomes of the events headache, chills, cold sweats, fever of 100.3 and severe body aches were resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 15Mar2021 at 12:15 (at the age of 63-years-old) as a single dose for COVID-19 immunization. Medical history included stroke, high blood pressure and diabetes. Concomitant medication was reported as prescriptions. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccine within four weeks prior to the COVID vaccine. On 16Mar2021 at 12:00, 24 hours after vaccination, the patient experienced diarrhoea for 24 hours. Therapeutic measures and treatments were not taken as a result of the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event diarrhoea was recovered on 17Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Chills, Dizziness, Dyspnoea
Clinical narrative: Tiredness; headache; muscle pain; chills; joint pain; fever; nausea; difficulty breathing; dizziness; weakness; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number; EN6199) via an unspecified route of administration in the left arm on 12Mar2021 at 12:00 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had allergies to  generic codons. Concomitant medications included allopurinol (MANUFACTURER UNKNOWN), atorvastatin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) from an unknown date and for unknown indications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. On 17Mar2021 at 12:00, 5 days after vaccination, the patient experienced tiredness, headache, muscle pain, chills, joint pain, fever, nausea, difficulty breathing/shortness of breath, dizziness and weakness. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office or clinic visit. The clinical outcome of the event tiredness, headache, muscle pain, chills, joint pain, fever, nausea, difficulty breathing/shortness of breath, dizziness and weakness were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Nausea, Pyrexia
Clinical narrative: Tiredness; headache; muscle pain; chills; joint pain; fever; nausea; difficulty breathing; dizziness; weakness; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number; EN6199) via an unspecified route of administration in the left arm on 12Mar2021 at 12:00 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had allergies to  generic codons. Concomitant medications included allopurinol (MANUFACTURER UNKNOWN), atorvastatin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) from an unknown date and for unknown indications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. On 17Mar2021 at 12:00, 5 days after vaccination, the patient experienced tiredness, headache, muscle pain, chills, joint pain, fever, nausea, difficulty breathing/shortness of breath, dizziness and weakness. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office or clinic visit. The clinical outcome of the event tiredness, headache, muscle pain, chills, joint pain, fever, nausea, difficulty breathing/shortness of breath, dizziness and weakness were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site swelling
Clinical narrative: injection site swollen; injection site itchy; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 23Mar2021 at 12:30 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure, overweight and allergy to nickel. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and metformin (MANUFACTURER UNKNOWN) for unknown indication. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, 1 week after the vaccination, the patient experienced vaccination site swelling and itchy. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events of vaccination site swelling and vaccination site pruritis was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Hypokinesia, Pain in extremity
Clinical narrative: can't lift arm up; left arm and shoulder still very painful; Painful from the shoulder blade to the fingers; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 23Mar2021 at 10:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included muscle disease and chronic fatigue syndrome. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 at 01:00, the patient's left arm and shoulder were still very painful and it was 8 days for now. The patient notified the doctor and had scheduled an appointment. It was painful from the shoulder blade to the fingers and the patient could not lift the arm up. The adverse events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcomes of the events left arm and shoulder still very painful, painful from the shoulder blade to the fingers and can't lift arm up were not resolved at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Dysgeusia, Energy increased
Clinical narrative: Metal taste, enchanted my taste buds and smells,; felt more energetic; This is a spontaneous report received from a non-contactable consumer, the patient. A 56-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration on 31Mar2021 at 08:00 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not receive any other concomitant medications within 2 weeks of vaccination. The patient had no known allergies to food, medications, or other products. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 31Mar2021 at 08:00, the patient experienced metal taste, enchanted his taste buds and smells, and felt more energetic. The patient did not received treatment for the reported events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the metallic taste and felt more energetic was resolved on 31Mar2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Diarrhoea, Fatigue, Headache
Clinical narrative: Neck ache; Loss of appetite; Sore vaccine site; Fatigue; Muscle aches; Chills; Diarrhea; Nausea; Very bad headache; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 at 09:45 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included low levels of thyroid (thyroid medication was being taken) and possible fibromyalgia. The patient was allergic to sulfa drugs and the patient had gluten sensitivity.  Concomitant medications included piroxicam (PAXIL), levothyroxine (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), vitamin-d nos (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 27Mar2021 at 15:00, the patient experienced mild symptoms of sore vaccine site, fatigue, moderate symptoms of muscle aches and chills for two days and more severe symptoms of diarrhoea, nausea, very bad headache and neck ache which had been for 4 to 5 days. The patient had loss of appetite due to nausea. The patient notified to primary physician as well. The patient did not receive any treatment for the events sore vaccine site, fatigue, muscle aches, chills, diarrhoea, nausea, headache, neck ache and decreased appetite. The clinical outcomes of the events sore vaccine site, fatigue, muscle aches, chills, diarrhoea, nausea, headache, neck ache and decreased appetite were not resolved at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Neck pain, Vaccination site pain
Clinical narrative: Neck ache; Loss of appetite; Sore vaccine site; Fatigue; Muscle aches; Chills; Diarrhea; Nausea; Very bad headache; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 at 09:45 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included low levels of thyroid (thyroid medication was being taken) and possible fibromyalgia. The patient was allergic to sulfa drugs and the patient had gluten sensitivity.  Concomitant medications included piroxicam (PAXIL), levothyroxine (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), vitamin-d nos (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 27Mar2021 at 15:00, the patient experienced mild symptoms of sore vaccine site, fatigue, moderate symptoms of muscle aches and chills for two days and more severe symptoms of diarrhoea, nausea, very bad headache and neck ache which had been for 4 to 5 days. The patient had loss of appetite due to nausea. The patient notified to primary physician as well. The patient did not receive any treatment for the events sore vaccine site, fatigue, muscle aches, chills, diarrhoea, nausea, headache, neck ache and decreased appetite. The clinical outcomes of the events sore vaccine site, fatigue, muscle aches, chills, diarrhoea, nausea, headache, neck ache and decreased appetite were not resolved at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: tested positive for COVID-19 in a PCR test; This is a spontaneous report received from a contactable consumer (patient) via medical information team. A 60-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: Unknown) via an unspecified route of administration on 11Mar2021 as dose 1, single for covid-19 immunisation. The patient medical history included heart condition. Patient concomitant medications were not reported. On 19Mar2021 Friday, the patient tested positive for COVID-19 in a PCR test. On 22Mar2021, patient got a monoclonal antibody infusion, and enquired how long should she wait before getting the 2nd dose. Patient informed that she was "homebound for almost a year" because of her heart condition, and mentioned that her husband seems to have gotten it [COVID-19] and asked if it would be possible to get infected before or after getting the first dose. The patient underwent lab tests and procedures which included PCR test: positive on 19Mar2021. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Migraine
Clinical narrative: Migraine type headache since receiving the 2nd dose; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 04Mar2021 at 15:00 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history included prostate cancer. The patient had no allergies to medications, food, or other products. Concomitant medications received within 2 weeks of vaccination included montelukast (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN), atorvastatin (MANUFACTURER UNKNOWN) and alprazolam (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Mar2021, at 18:00, the patient experienced migraine type headache. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Treatment received for the adverse events was reported as no. The clinical outcome of the event migraine type headache was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Rash erythematous, Rash pruritic
Clinical narrative: Itchy redness on arm, chest, stomach and legs; Extreme tiredness; Itchy redness on arms, chest, stomach, and legs; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 24Mar2021 at 12:30 (at the age of 66-years-old), as a single dose for COVID-19 immunization. The patient did not have any relevant medical history. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had any no known allergies to medications, food or other products. On 29Mar2021 at 06:00, the patient experienced itchy redness on arm, chest, stomach and legs also accompanied by extreme tiredness. On 30Mar2021, the adverse reaction intensified and continued till 31Mar2021 and on same day, the patient visited dermatologist and prescriptions was given. The events resulted in doctor or other healthcare professional office/clinic visit (patient visited dermatologist). Therapeutic measures were taken as a result of itchy redness on arm, chest, stomach and legs included prednisone and hydroxyzine as well as over the counter products PEPCID and ZYRTEC. The clinical outcome of the events itchy redness on arm, chest, stomach and legs and extreme tiredness was not resolved at the time of reporting.    No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Contusion, Decreased appetite, Dizziness, Headache
Clinical narrative: Nausea; Vomiting; dizziness; bruising; lost of appetite; headache; chills; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 16Mar2021 at 09:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had received unspecified medications (described as prescription) within 2weeks of vaccine. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 17Mar2021 at 01:00, the patient experienced nausea, vomiting, dizziness, bruising, lost of appetite, headache and chills. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse event. The clinical outcome of the events nausea, vomiting, dizziness, bruising, appetite lost, headache and chills were resolving at the time of reporting.  No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vomiting
Clinical narrative: Nausea; Vomiting; dizziness; bruising; lost of appetite; headache; chills; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 16Mar2021 at 09:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had received unspecified medications (described as prescription) within 2weeks of vaccine. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 17Mar2021 at 01:00, the patient experienced nausea, vomiting, dizziness, bruising, lost of appetite, headache and chills. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse event. The clinical outcome of the events nausea, vomiting, dizziness, bruising, appetite lost, headache and chills were resolving at the time of reporting.  No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Rash papular, Rash pruritic
Clinical narrative: Raised itchy Rash on right breast and neck and chest; itchy Rash on right breast and neck and chest; This is a spontaneous report received from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8732) via an unspecified route of administration in the arm right on 27Mar2021 at 13:00 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history included birth control.  The concomitant medications included ethinylestradiol, norgestrel (CRYSELLE) indicated for birth control since an unspecified date. Allergic history to medications, food, or other products was reported as not known. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. On 29Mar2021 at 00:00, the patient experienced raised itchy rash on right breast and neck and chest. The clinical outcome of the event raised rash, itchy rash on right breast and neck and chest was not recovered at the time of report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.